Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

VLP Therapeutics Japan

Request full access

Next-generation vaccines for cancer and infectious diseases

Tokyo, JapanFounded 2020Biotech & Life Sciences

About VLP Therapeutics Japan

VLP Therapeutics Japan is the Japanese subsidiary of VLP Therapeutics, established in Tokyo in 2020 to accelerate vaccine development and manufacturing in Japan, particularly for next-generation RNA vaccines.

The subsidiary focuses on advancing vaccines based on the company’s self-amplifying RNA (replicon) technology, which allows vaccine RNA to replicate within cells, enabling effective immune responses at lower doses than conventional mRNA vaccines. This platform is designed to improve vaccine safety, reduce production costs, and support rapid manufacturing during global health emergencies.

VLP Therapeutics Japan is leading the development of COVID-19 vaccine candidates (including VLPCOV-01 and VLPCOV-02) using the replicon platform. These programs are supported by Japanese government initiatives, including funding and collaboration through the Japan Agency for Medical Research and Development (AMED).

Beyond COVID-19 vaccines, the subsidiary supports the broader pipeline of VLP Therapeutics by contributing to clinical development, regulatory coordination, and manufacturing infrastructure in Japan.

To strengthen its research and production capabilities, VLP Therapeutics Japan is establishing a vaccine manufacturing facility at Kurume Research Park in Fukuoka, which is intended to support both clinical development and rapid response to future infectious disease outbreaks.

Through this expansion in Japan, the company aims to bridge U.S. research innovation with Japanese clinical development and manufacturing, accelerating the commercialization of next-generation vaccines.

Source: Dealroom company data

VLP Therapeutics Japan in the Tokyo ecosystem

Live from Dealroom

The VLP Therapeutics Japan office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed3 investors entered at this stage

  • AMED
  • Japanese Ministry of Economy, Trade and Industry
  • Global Health Innovative Technology Fund

Series B and later1 investor entered at this stage

  • Sumitomo Mitsui Trust Bank
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇯🇵 Japan · Tokyo HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about VLP Therapeutics Japan on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See VLP Therapeutics Japan on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.